Philip Hampton to step down from chairman role at GSK
January 21, 2019Sales and Marketing Chairman, GSK, GlaxoSmithKline, appointment, philip hampton
Sir Philip Hampton is stepping down from his role as non-executive chairman of British multinational GlaxoSmithKline. The resignation comes just …
NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma
January 21, 2019Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma
Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …
Sun Pharma’s shares hit six-year low after further whistleblower allegations emerge
January 18, 2019Medical Communications India, Sun Pharma, pharma
Sun Pharma has seen its shares fall by 12% to an almost six-year low after it was rocked by allegations …
Top Ten most popular articles on Pharmafile.com this week!
January 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Netherlands, Novo Nordisk, Roche, astra zeneca, prcing, sequiris, top 10, uk politics
Job switches were the theme of this week as AstraZeneca lost three, high levels executives to biotechs amid a restructuring …
Pharmacists warn of shortages in England
January 18, 2019Medical Communications access, pharmacists, pricing, shortages
Pharmacists in England have warned that they are struggling to obtain many common generic medicines, as the number of medicines …
Canada Health approves Novartis’ CAR-T therapy Kymriah
January 18, 2019Medical Communications CAR T, CAR-T, Canada, Cancer, Kymriah, Novartis, oncology
Health Canada has approved Novartis’ CAR-T therapy Kymriah for use in paediatric and young adult patients aged between three and …
Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE
January 18, 2019Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma
A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …
Scientists prevent axon self-destruct mechanism using gene therapy
January 17, 2019Research and Development Axon, gene therapy, health, neuropathy
Scientists at the University of Washington have developed a gene therapy that prevents the process through which axons (nerve fibres) …
Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer
January 17, 2019Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma
Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …
More young people surviving cancer in England, despite significant economic divide
January 17, 2019Medical Communications, Research and Development Cancer, England, UK, health public health, oncology, young people
Mortality and five year survival rates in a range of different cancers among people aged 13-24 improved in England between …
Abbott to boost heart valve therapy portfolio with acquisition of Cephea Valve Technologies
January 17, 2019Manufacturing and Production, Sales and Marketing Abbott, Cephea, acquistion, mitral valve disease, pharma
As mergers and acquisitions pick up again for the New Year, Abbott has revealed plans to buy medical device firm …
Sacklers accused of personally directing deceptive OxyContin sales tactics
January 17, 2019Sales and Marketing OxyContin, Purdue Pharma, opidois, opioid crisis, pain, sackler
Members of the billionaire Sackler dynasty personally directed efforts to mislead doctors and patients as to the dangers of the …
US regulator to recruit 50 new gene and cell therapy clinical reviewers
January 16, 2019Research and Development FDA, cell therapy, gene therapy, regulation
FDA Commissioner Scott Gottlieb has said that the agency hopes to recruit 50 additional clinical reviewers for the group that …
MSD’s Keytruda boosts overall survival by 31% in advanced oesophageal cancer
January 16, 2019Research and Development Cancer, MSD, keytruda, oesophageal cancer, pharma
MSD has unveiled new Phase 3 data for its blockbuster anti-PD-1 immunotherapy Keytruda (pembrolizumab), showing that the drug succeeded in …
Breast cancer cells can be transformed into fat cells using combination therapy, study shows
January 16, 2019Research and Development Cancer, EMT, breast cancer, cells, oncology, tumours
An innovative cancer treatment can turn malignant breast cancer cells into fat cells, thus preventing the formation of metastases (the …
Novo Nordisk Pharmatech A/S signs distribution agreement with DKSH for eleven markets in Asia Pacific
January 16, 2019Manufacturing and Production, Medical Communications, Research and Development DKSH, Novo Nordisk, pharma
DKSH’s Business Unit Performance Materials, a leading ingredients and specialty chemicals distributor, will distribute Novo Nordisk Pharmatech’s pharmaceutical grade compounds …
FDA halts allergy drug approval process due to government shutdown
January 15, 2019Research and Development Aimmune, FDA, Trump, governmetn, shutdown
California-based pharma firm, Aimunne Therapeutics has been notified that due to the government shutdown, the US Food and Drug Administration …
Former CEO of Novartis’ US operations joins board of cancer immunotherapy firm
January 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
ImmunSYS, a Fort Lauderdale, Florida-based firm focused on the development of innovative cancer immunotherapy products, today announced that Douglas G …
Tumours with large number of mutations respond better to immunotherapies, study shows
January 15, 2019Manufacturing and Production, Research and Development Cancer, immunotherapy, nature, oncology, research, tumour
Tumours with a large number of DNA mutations are more likely to respond to immunotherapies than cancers with fewer mutations, …
Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD
January 15, 2019Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma
Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
